In Vivo Disruption of Tolerogenic Cross-presentation Mechanisms Uncovers an Effective T-cell Activation by B-cell Lymphomas Leading to Antitumor Immunity
Bone marrow-derived antigen-presenting cells (APCs) play a central role in the induction of tolerance to tumor antigens expressed by B-cell lymphomas. Here we show that in vivo disruption of this APC-mediated tolerogenic mechanism unveils an intrinsic ability of malignant B cells to efficiently present tumor antigens to antigen-specific CD4+ T cells, resulting in a strong antitumor effect. This intrinsic antigen-presenting ability of malignant B cells is, however, overridden by tolerogenic bone marrow-derived APCs, leading instead to T-cell unresponsiveness and lack of antitumor effect. These results highlight the concept that therapeutic strategies aimed at enhancing the antigen-presenting function of B-cell lymphomas might not succeed unless the tolerogenic mechanisms mediated by bone marrow-derived APCs are disrupted in the first place.
Digital Object Identifier (DOI)
Citation / Publisher Attribution
Blood, v. 7, p. 2871-2878
Scholar Commons Citation
Horna, Pedro; Cuenca, Alex; Cheng, Fengdong; Brayer, Jason; Wang, Hong-Wei; Borrello, Ivan; Levitsky, Hyam; and Sotomayor, Eduardo M., "In Vivo Disruption of Tolerogenic Cross-presentation Mechanisms Uncovers an Effective T-cell Activation by B-cell Lymphomas Leading to Antitumor Immunity" (2006). Oncologic Sciences Faculty Publications. 33.
Was this content written or created while at USF?